TY - JOUR
T1 - Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders
AU - Koeffler, H. P.
AU - Heitjan, D.
AU - Mertelsmann, R.
AU - Kolitz, J. E.
AU - Schulman, P.
AU - Itri, L.
AU - Gunter, P.
AU - Besa, E.
PY - 1988
Y1 - 1988
N2 - A double-blind, placebo-controlled randomized trial of 13-cis retinoic acid was performed to determine if the drug has a therapeutic effect in patients with myelodysplastic syndromes (MDS). Sixty-eight evaluable patients with MDS were randomized to receive a single, daily oral dose of either 13-cis retinoic acid (13-CRA, 100 mg/m2) or matching placebo. Treatment was continued, when possible, for a period of 6 months. Determination of response to treatment was based on clinical course, repeat bone marrow biopsies, and aspirates and blood counts (CBC) with WBC differential, platelet, and reticulocyte numbers at specified intervals. No significant difference was noted between the two treatment groups in response to test drug (P = .66). One patient (3%) in the 13-CRA group and two patients (6%) in the placebo group had a minor response. Approximately 30% of patients in both groups had progression of their disease, and progression-free survival was nearly identical. Greater than 90% of the patients receiving 13-CRA developed mild or moderate skin toxicity that was reversible with decreasing or discontinuing the drug. Our study did not find that 13-CRA exerts a beneficial therapeutic effect in patients with MDS.
AB - A double-blind, placebo-controlled randomized trial of 13-cis retinoic acid was performed to determine if the drug has a therapeutic effect in patients with myelodysplastic syndromes (MDS). Sixty-eight evaluable patients with MDS were randomized to receive a single, daily oral dose of either 13-cis retinoic acid (13-CRA, 100 mg/m2) or matching placebo. Treatment was continued, when possible, for a period of 6 months. Determination of response to treatment was based on clinical course, repeat bone marrow biopsies, and aspirates and blood counts (CBC) with WBC differential, platelet, and reticulocyte numbers at specified intervals. No significant difference was noted between the two treatment groups in response to test drug (P = .66). One patient (3%) in the 13-CRA group and two patients (6%) in the placebo group had a minor response. Approximately 30% of patients in both groups had progression of their disease, and progression-free survival was nearly identical. Greater than 90% of the patients receiving 13-CRA developed mild or moderate skin toxicity that was reversible with decreasing or discontinuing the drug. Our study did not find that 13-CRA exerts a beneficial therapeutic effect in patients with MDS.
UR - http://www.scopus.com/inward/record.url?scp=0023900682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023900682&partnerID=8YFLogxK
U2 - 10.1182/blood.v71.3.703.703
DO - 10.1182/blood.v71.3.703.703
M3 - Article
C2 - 3278754
AN - SCOPUS:0023900682
SN - 0006-4971
VL - 71
SP - 703
EP - 708
JO - Blood
JF - Blood
IS - 3
ER -